Actively Recruiting

Phase 3
Age: 0Hours - 36Hours
All Genders
Healthy Volunteers
ID06893939

Limited Versus Extended Trophic Feeding (LET-FEED) Trial Comparing Early and Delayed Advancement of Enteral Feeds in Very Preterm Infants

Led by University of Washington · Updated on 2025-07-28

350

Participants Needed

6

Research Sites

12 weeks

Total Duration

On this page

Sponsors

U

University of Washington

Lead Sponsor

U

University of Alabama at Birmingham

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the best timing to advance enteral feeding in very preterm infants born between 25 and 31 weeks gestation who weigh less than 1500 grams at birth. The study aims to find out if starting to increase milk feeds earlier, after one day of small "trophic" feeds, compared to after three days of trophic feeds, reduces the risk of late-onset sepsis (a serious infection occurring after the first 3 days of life) without causing more complications. This multi-center, randomized controlled trial compares these two feeding strategies to improve survival and health outcomes in these vulnerable newborns. Infants will be randomly assigned to one of two feeding plans: limited trophic feeds for about 24 hours or extended trophic feeds for about 72 hours, both at volumes of 20-25 mL/kg/day. After the assigned trophic feeding period, enteral feeds will be advanced by about 25-30 mL/kg/day until full feeding volumes of 140 mL/kg/day are reached, typically within two weeks. The feeds consist of the infant’s own mother's milk or donor human milk if the mother's milk is unavailable. The study allows adjustments if signs of feeding intolerance occur. Participants will be closely monitored throughout their hospital stay until around 40 weeks corrected gestational age. Researchers will assess the occurrence of culture-proven late-onset sepsis, length of hospital stay, death, use of intravenous nutrition and central lines, and other complications like necrotizing enterocolitis, brain hemorrhages, lung disease, and eye problems. Growth measurements such as weight, length, and head size changes will also be tracked. This thorough monitoring aims to determine the safest and most effective feeding approach for very preterm infants.

CONDITIONS

Brief Title

Limited Versus Extended Trophic Feeding (LET-FEED) Trial

Who Can Participate

Age: 0Hours - 36Hours
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Birthweight less than 1500 grams
  • Born between 25 weeks 0 days and 31 weeks 6 days gestation
  • Consent given to feed donor milk if mother's own milk is unavailable or insufficient
Not Eligible

You will not qualify if you...

  • Birthweight below the 5th percentile for age based on growth curves
  • Parent or legal guardian unable to provide consent within 36 hours after birth
  • Major congenital anomalies affecting feeding decisions (e.g., gastroschisis, omphalocele, congenital diaphragmatic hernia, congenital heart disease)
  • Known genetic conditions affecting growth, feeding, or survival
  • Use of vasopressor medications (other than hydrocortisone) within first 24 hours after birth
  • Considered terminally ill with limited support decisions made or planned

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 36 hours after birth

Participants are screened for eligibility to participate in the trial.

1 visit (in-person, consent and enrollment)

Treatment

Duration - Up to 2 weeks or until full feeding volumes are reached

Participants receive either limited trophic feeding for 24 hours or extended trophic feeding for 72 hours, followed by progressive advancement of enteral feeds until full feeds are reached. Feeding consists of parent's own milk or donor human milk. Intravenous fluids and nutrition are provided as needed until full enteral feeding is established.

Daily clinical care visits during hospitalization

Monitoring

Duration - Up to hospital discharge, approximately 40 weeks' gestation

Participants are monitored for late onset sepsis and other clinical outcomes until discharge from the neonatal intensive care unit, around 40 weeks' gestation.

Ongoing assessments during hospitalization

Trial Site Locations

Total: 6 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Not Yet Recruiting

2

University of South Florida

Tampa, Florida, United States, 33606

Not Yet Recruiting

3

University of Oklahoma

Oklahoma City, Oklahoma, United States, 73104

Not Yet Recruiting

4

Baylor College of Medicine

Houston, Texas, United States, 77030

Not Yet Recruiting

5

University of Washington

Seattle, Washington, United States, 98195

Not Yet Recruiting

6

St. Joseph's Medical Center

Tacoma, Washington, United States, 98405

Actively Recruiting

Loading map...

Research Team

G

Gregory C Valentine, MD MED FAAP

A

Ariel Salas, MD, MSPH

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Active 24 Hours Subperiostal vs. Passive Subdural Drainage A...

Chronic Subdural Hematoma

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Longitudinal development of the gut microbiome and metabolome in preterm neonates with late onset sepsis and healthy controls.

Christopher J Stewart, Nicholas D Embleton, Emma C L Marrs...

https://pubmed.ncbi.nlm.nih.gov/28701177

Gut Dysbiosis, Bacterial Colonization and Translocation, and Neonatal Sepsis in Very-Low-Birth-Weight Preterm Infants.

Chien-Chung Lee, Ye Feng, Yuan-Ming Yeh...

https://pubmed.ncbi.nlm.nih.gov/34690993

Donor human milk for preventing necrotising enterocolitis in very preterm or very low-birthweight infants.

Maria Quigley, Nicholas D Embleton, Nicholas Meader...

https://pubmed.ncbi.nlm.nih.gov/39239939